The aim of this randomized controlled trial (RCT) was to investigate whether pancrelipase protects against nonalcoholic fatty liver disease (NAFLD) development after pancreatoduodenectomy in patients with pancreatic cancer better than conventional pancreatic enzyme supplementation.

Methods

A total of 57 patients were randomly assigned to the study group (n = 29; pancrelipase replacement therapy) or the control group (n = 28; conventional pancreatic enzyme supplementation). NAFLD was defined as a liver-to-spleen attenuation ratio less than 0.9 on CT. Clinical and laboratory findings were also assessed.

Results

NAFLD was observed in 6/29 patients (21%) in the study group, and 11/28 patients (39%) in the control group, but this was not a statistically significant difference. In the control group, crossover to pancrelipase replacement therapy upon NAFLD diagnosis produced improvement in five out of 10 patients. Multivariate analysis showed that advanced age and extended resection were independent risk factors for NAFLD development.

Conclusion

This RCT did not show a significant protective effect of pancrelipase replacement therapy over conventional pancreatic enzyme supplementation on NAFLD development after pancreatoduodenectomy for pancreatic cancer. Further studies are clearly required to investigate the etiology of and new therapeutic strategies for treatment-resistant NAFLD (UMIN 000019817).

References

1Buchler MW, Wagner M, Schmied BM, Uhl W, Friess H, Z'graggen K. Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy. Arch Surg. 2003; 138: 1310–4.
10.1001/archsurg.138.12.1310
PubMed Web of Science® Google Scholar
2Lieberman MD, Kilburn H, Lindsey M, Brennan MF. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg. 1995; 222: 638–45.
10.1097/00000658-199511000-00006
CAS PubMed Web of Science® Google Scholar
3Gouma DJ, van Geenen RC, van Gulik TM, de Haan RJ, de Wit LT, Busch OR, et al. Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. Ann Surg. 2000; 232: 786–95.
10.1097/00000658-200012000-00007
CAS PubMed Web of Science® Google Scholar
4de Wilde RF, Besselink MG, van der Tweel I, de Hingh IH, van Eijck CH, Dejong CH, et al. Impact of nationwide centralization of pancreatoduodenectomy on hospital mortality. Br J Surg. 2012; 99: 404–10.
10.1002/bjs.8664
PubMed Web of Science® Google Scholar
5Kato H, Isaji S, Azumi Y, Kishiwada M, Hamada T, Mizuno S, et al. Development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) after pancreatoduodenectomy: proposal of a postoperative NAFLD scoring system. J Hepatobiliary Pancreat Sci. 2010; 17: 296–304.
10.1007/s00534-009-0187-2
CAS PubMed Web of Science® Google Scholar
6Nomura R, Ishizaki Y, Suzuki K, Kawasaki S. Development of hepatic steatosis after pancreatoduodenectomy. AJR Am J Roentgenol. 2007; 189: 1484–8.
10.2214/AJR.07.2809
PubMed Web of Science® Google Scholar
7Song SC, Choi SH, Choi DW, Heo JS, Kim WS, Kim MJ. Potential risk factors for nonalcoholic steatohepatitis related to pancreatic secretions following pancreatoduodenectomy. World J Gastroenterol. 2011; 17: 3716–23.
10.3748/wjg.v17.i32.3716
CAS PubMed Web of Science® Google Scholar
8Tanaka N, Horiuchi A, Yokoyama T, Kaneko G, Horigome N, Yamaura T, et al. Clinical characteristics of de novo nonalcoholic fatty liver disease following pancreatoduodenectomy. J Gastroenterol. 2011; 46: 758–68.
10.1007/s00535-011-0370-5
CAS PubMed Web of Science® Google Scholar
9Yu HH, Shan YS, Lin PW. Effect of pancreatoduodenectomy on the course of hepatic steatosis. World J Surg. 2010; 34: 2122–7.
10.1007/s00268-010-0636-8
PubMed Web of Science® Google Scholar
10Nakanuma Y, Ohta G, Konishi I, Shima Y. Liver injury with perivenular fibrosis and alcoholic hyalin after pancreatoduodenectomy for pancreatic carcinoma. Acta Pathol Jpn. 1987; 37: 1953–60.
10.1111/j.1440-1827.1987.tb03309.x
CAS PubMed Web of Science® Google Scholar
11Dresler CM, Fortner JG, McDermott K, Bajorunas DR. Metabolic consequences of (regional) total pancreatectomy. Ann Surg. 1991; 214: 131–40.
10.1097/00000658-199108000-00007
CAS PubMed Web of Science® Google Scholar
12Gubergrits N, Malecka-Panas E, Lehman GA, Vasileva G, Shen Y, Sander-Struckmeier S, et al. A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery. Aliment Pharmacol Ther. 2011; 33: 1152–61.
10.1111/j.1365-2036.2011.04631.x
CAS PubMed Web of Science® Google Scholar
13Whitcomb DC, Lehman GA, Vasileva G, Malecka-Panas E, Gubergrits N, Shen Y, et al. Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial. Am J Gastroenterol. 2010; 105: 2276–86.
10.1038/ajg.2010.201
CAS PubMed Web of Science® Google Scholar
14Nagai M, Sho M, Satoi S, Toyokawa H, Akahori T, Yanagimoto H, et al. Effects of pancrelipase on nonalcoholic fatty liver disease after pancreatoduodenectomy. J Hepatobiliary Pancreat Sci. 2014; 21: 186–92.
10.1002/jhbp.14
Web of Science® Google Scholar
15Sanyal AJ. Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol. 2005; 2: 46–53.
10.1038/ncpgasthep0084
CAS PubMed Web of Science® Google Scholar
16Okamura Y, Sugimoto H, Yamada S, Fujii T, Nomoto S, Takeda S, et al. Risk factors for hepatic steatosis after pancreatectomy: a retrospective observational cohort study of the importance of nutritional management. Pancreas. 2012; 41: 1067–72.
10.1097/MPA.0b013e31824c10ab
PubMed Web of Science® Google Scholar
17Ishihara R, Gregory P, Koch HF, Kolleck S, Moesseler A, Kamphues J, Uchida I. Comparison study of pharmacological efficacy of pancreatic digestive enzyme replacement and of digestive enzymes on digestibility of fat, protein and starch in a minipig model of pancreatic exocrine insufficiency (in vivo). J New Rem and Clin. (in Japanese) 2012; 61: 1044–53.
Google Scholar
18Kishi Y, Shimada K, Nara S, Esaki M, Kosuge T. Administration of pancrelipase as effective treatment for hepatic steatosis after pancreatectomy. Pancreas. 2015; 44: 983–7.
10.1097/MPA.0000000000000356
CAS PubMed Web of Science® Google Scholar
19Nakagawa N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, et al. Nonalcoholic fatty liver disease after pancreatoduodenectomy is closely associated with postoperative pancreatic exocrine insufficiency. J Surg Oncol. 2014; 110: 720–6.
10.1002/jso.23693
CAS PubMed Web of Science® Google Scholar
20Kato K, Isaji S, Kawarada Y, Hibasami H, Nakashima K. Effect of zinc administration on pancreatic regeneration after 80% pancreatectomy. Pancreas. 1997; 14: 158–65.
10.1097/00006676-199703000-00008
CAS PubMed Web of Science® Google Scholar
21Sato R, Kishiwada M, Kuriyama N, Azumi Y, Mizuno S, Usui M, et al. Paradoxical impact of the remnant pancreatic volume and infectious complications on the development of nonalcoholic fatty liver diseaseafter pancreatoduodenectomy. J Hepatobiliary Pancreat Sci. 2014; 21: 562–72.
10.1002/jhbp.115
CAS PubMed Web of Science® Google Scholar
22Yamazaki S, Takayama T, Higaki T, Moriguchi M, Yoshida N, Miyazaki T, et al. Pancrelipase with branched-chain amino acids for preventing nonalcoholic fatty liver disease after pancreaticoduodenectomy. J Gastroenterol. 2016; 51: 55–62.
10.1007/s00535-015-1077-9
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume23, Issue3

March 2016

Pages 167-173

Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreatoduodenectomy in patients with pancreatic cancer? A randomized controlled trial

Abstract

Background

Methods

Results

Conclusion

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreatoduodenectomy in patients with pancreatic cancer? A randomized controlled trial

Abstract

Background

Methods

Results

Conclusion

References

Citing Literature

References

Related

Information